- Home
- CMIIU vs OSRHW Comparison
CMIIU vs OSRHW Comparison
Compare CMIIU & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMIIU | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2026 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CMIIU | OSRHW |
|---|---|---|
| Price | $10.00 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.2K | ★ 18.9K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.94 | $0.03 |
| 52 Week High | $10.15 | $0.08 |
Technical Indicators
Market Signals| Indicator | CMIIU | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 48.03 |
| Support Level | N/A | $0.04 |
| Resistance Level | $10.01 | $0.06 |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 100.00 | 39.22 |
Price Performance
Historical ComparisonAbout CMIIU Columbus Circle Capital Corp II Unit
Columbus Circle Capital Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.